Press Releases

and/or
565 News Releases found
Memorial Sloan Kettering Cancer Center (MSK) is partnering with DigitasLBi and Phase2 to help expand MSK's digital reach.
Craig Thompson
Memorial Sloan Kettering and Quest Diagnostics announced a joint collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors.
Pictured: Marie-Josée and Henry R. Kravis
Memorial Sloan Kettering launched the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, an ambitious initiative to improve cancer care and research through genomic analysis.
Pictured: Mark Kris
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Pictured: William Tap
New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.
Three winners of the first-ever Breakthrough Prizes — Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.
Memorial Sloan Kettering has launched a collaborative translational research center that will unite researchers specializing in two rapidly growing fields: molecular imaging and nanotechnology.
cancer cell
New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.
Memorial Sloan Kettering announced the appointment of Pereira & O’Dell in New York as its creative agency of record and Media Storm as its media agency of record.
Pictured: Renier Brentjens, Isabelle Rivière, and Michel Sadelain
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.